Content continues after advertisement

Concurrent Canine Hyperadrenocorticism & Diabetes Mellitus

Jinelle Webb, DVM, MSc, DVSc, DACVIM (SAIM), Mississauga Oakville Veterinary Emergency Hospital, Oakville, Canada

Sign in to Print/View PDF

In the Literature

Miceli DD, Pignataro OP, Castillo VA. Concurrent hyperadrenocorticism and diabetes mellitus in dogs. Res Vet Sci. 2017;115:425-431.


FROM THE PAGE …

This study of 235 dogs with pituitary- or adrenal-dependent hyperadrenocorticism (HAC) examined the co-occurrence of diabetes mellitus (DM) and HAC and evaluated risk factors for development of DM in dogs with HAC. Dogs were divided into 3 groups (ie, fasting blood glucose <100 mg/dL, fasting blood glucose between 100 mg/dL and 180 mg/dL, fasting blood glucose >180 mg/dL). Parameters assessed included triglyceride level, cholesterol, urine cortisol:creatinine ratio, age, sex, breed, neuter status, BCS, cause of HAC, and median survival time.

DM occurred in conjunction with HAC in 13.61% of study dogs. Risk for developing DM was higher in dogs with a fasting glucose >100 mg/dL, even in patients in which overt DM was not yet apparent. This suggests that dogs with HAC can experience a prediabetic state that may progress to clinical DM.

Other risk factors for development of DM included presence of pituitary-dependent HAC, urine cortisol:creatinine ratio >100 × 10-6, and intact status for female dogs. In addition, there was a trend toward increased risk in dogs with cholesterol levels >351 mg/dL or triglyceride levels >221 mg/dL. These findings support reducing hypercortisolemia as effectively as possible, as the degree of control is likely related to risk for developing concurrent DM.

In this cohort of dogs, obesity did not increase risk for developing DM. Purebred dogs were also not at increased risk as compared with crossbreed dogs. It is possible that obesity was partially corrected with treatment for HAC and resulted in improved response to endogenous insulin.

Median survival time was shorter in dogs with both concurrent HAC and DM as compared with those with HAC alone. Recognition of risk factors linked to development of DM, and early intervention to address these risk factors, may reduce the number of patients with HAC that develop overt DM.


… TO YOUR PATIENTS

Key pearls to put into practice:

1

Controlling hypercortisolemia in dogs with HAC may decrease risk for development of concurrent DM.

 

2

Obesity in dogs with HAC does not appear to increase the risk for developing DM.

 

3

Early recognition and intervention to address risk factors may reduce incidence of concurrent DM development in dogs with HAC.

 

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief: The Podcast

Listen as host Beckie Mossor, RVT, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Privacy Policy (Updated 05/08/2018) Terms of Use (Updated 05/08/2018)